| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA297: Ocriplasmin for treating vitreomacular traction |
|
Medicine details |
|
| Medicine name | ocriplasmin (Jetrea®) |
| Formulation | 0.5 mg/2 ml concentrate for solution for injection |
| Reference number | 1502 |
| Indication | Treatment of vitreomacular traction (VMT) in adults, including when associated with macular hole of diameter less than or equal to 400 microns |
| Company | ThromboGenics NV |
| BNF chapter | Eye |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 31/05/2013 |
| NICE guidance | |